



Australian Government
Department of Health
Therapeutic Goods Administration

Public Summary

Summary for ARTG Entry:	336190	MediHerb Vitanox
ARTG entry for	Medicine Listed	
Sponsor	Integria Healthcare Australia Pty Ltd	
Postal Address	PO Box 4854, EIGHT MILE PLAINS, QLD, 4113 Australia	
ARTG Start Date	12/05/2020	
Product Category	Medicine	
Status	Active	
Approval Area	Listed Medicines	

Conditions

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

Products

1 . MediHerb Vitanox

Product Type	Single Medicine Product	Effective Date	4/03/2021
---------------------	-------------------------	-----------------------	-----------

Permitted Indications

Antioxidant/Reduce free radicals formed in the body

Helps reduce/decrease free radical damage to body cells

Maintain/support general health and wellbeing

Maintain/support healthy blood circulation

Maintain/support blood circulation/flow to the peripheral areas of the body (legs, hands and feet)

Maintain/support blood capillary health

Maintain/support blood vessel health

Indication Requirements

Product presentation must not imply or refer to circulatory disorders/diseases/conditions e.g. thrombosis.

Product presentation must not imply or refer to serious cardiovascular conditions.

Standard Indications

No Standard Indications included on Record

Specific Indications

No Specific Indications included on Record

Warnings

Adults only.

Caffeine intake more than 200 mg per day is not recommended during pregnancy or breastfeeding.

If symptoms persist, seek the advice of a healthcare professional.

Contains caffeine [state quantity per dosage unit or per mL or per gram of product] total caffeine [per dosage unit or per mL or per gram]. A cup of instant coffee contains approximately 80mg of caffeine.

For practitioner dispensing only.

Additional Product information

Pack Size/Poison information



Australian Government
Department of Health
Therapeutic Goods Administration

Pack Size

Poison Schedule

Components

1 . Formulation 1

Dosage Form Tablet, film coated

Route of Administration Oral

Visual Identification

Active Ingredients

Camellia sinensis leaf Extract dry concentrate standardised	166.7 mg
Equivalent: Camellia sinensis (Dry)	4.168 g
Curcuma longa rhizome Extract dry concentrate standardised	80 mg
Equivalent: Curcuma longa (Dry)	2 g
Rosmarinus officinalis leaf Extract dry concentrate	200 mg
Equivalent: Rosmarinus officinalis (Dry)	1 g
Vitis vinifera seed Extract dry concentrate standardised	50 mg
Equivalent: Vitis vinifera (Dry)	6 g

Other Ingredients (Excipients)

calcium hydrogen phosphate dihydrate
colloidal anhydrous silica
hypromellose
magnesium stearate
maltodextrin
microcrystalline cellulose
sodium starch glycollate
sorbitol

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.

Public Summary